• Explore /
  • Poster
  • / ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Geraldine Martineau

Clinical Research Department, Institut Gustave Roussy, Villejuif, France

Geraldine Martineau , Stéphanie Foulon , Jean-Christophe Eymard , Yohann Loriot , Giulia Baciarello , Jean Francois Berdah , Carole Helissey , Pernelle Lavaud , Florence Joly , Nadia Zaghdoud , Anne Sophie Hue , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03314324

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS5093)

DOI

10.1200/JCO.2018.36.15_suppl.TPS5093

Abstract #

TPS5093

Poster Bd #

316b

Abstract Disclosures

Similar Posters

First Author: Geraldine Martineau

First Author: Siyuan S Guo

First Author: Alyssa Liang

First Author: Alexander Shiang